Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$59.03 USD

59.03
7,494,737

+0.46 (0.79%)

Updated Jun 5, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

New Strong Sell Stocks for June 16th

ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.

Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Q1 Earnings and Revenues Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte

Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Fomento Economico Mexicano, NextEra Energy & Charter Communications

Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Charter Communications, Inc. (CHTR).

The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio

Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.

Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?

Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates

Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Molina Healthcare (MOH) in Q1 Earnings?

Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.

Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo

Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks

Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.

Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan

Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.

Company News for Mar 27, 2023

Companies in The News Are: SQ,INCY,JPM,WFC

Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment

Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.

Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II

Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.

Incyte (INCY) Down 8.3% Since Last Earnings Report: Can It Rebound?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.